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The impact of the revised Clinical and Laboratory Standards 
Institute interpretative criteria for cefepime in Enterobacteriaceae 
remains unclear. We applied the new breakpoint on 644 previ-
ously defined cefepime-susceptible Enterobacteriaceae isolates. 
We found no differences in mortality or microbiological failure, 
regardless of isolates being susceptible or cefepime-susceptible 
dose-dependent by current criteria.
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In 2014, the Clinical and Laboratory Standards Institute (CLSI) 
revised the interpretive criteria for cefepime susceptibility 
among Enterobacteriaceae. Under the former criteria, Kirby-
Bauer disk diffusion zone diameter for cefepime-susceptible, 
-intermediate, and -resistant interpretive criteria were as fol-
lows: ≥18  mm (minimum inhibitory concentration [MIC], 
≤8 μg/mL), 15–17 mm (MIC, 16 μg/mL), and ≤14 mm (MIC, 
≥32  μg/mL). In 2014, they were re-categorized as susceptible 
(≥25 mm; MIC, ≤2 μg/mL), susceptible dose-dependent (SDD; 
19–24  mm; MIC, 4–8  μg/mL), and resistant (≤18  mm; MIC, 
≥16 μg/mL). The intermediate category was discontinued [1].
Several retrospective studies have since investigated the clin-
ical impact of new cefepime breakpoint in Enterobacteriaceae 
infections and concluded that Gram-negative infections with 
higher MICs or cefepime-SDD isolates were associated with 
increased mortality. However, these studies were limited by 
including non-Enterobacteriaceae bacteremias, polymicrobial 
infections, and combination antimicrobial therapy [2–6]. We 
aim to determine if Enterobacteriaceae bacteremia isolates, pre-
viously identified as cefepime-susceptible and now reclassified 
as cefepime-SDD by the 2014 CLSI criteria, are associated with 
higher mortality and microbiological failure when compared 




We performed a retrospective cohort study from January 2005 
through December 2013 at a 1250-bed teaching hospital. We 
included all inpatients aged ≥18 years with a blood culture(s) 
positive for Enterobacteriaceae who received cefepime within 24 
hours before or after the first positive blood culture.
Cohort
Patients were excluded if they met any of the following exclu-
sion criteria: (1) Enterobacteriaceae with a cefepime disk dif-
fusion diameter ≤18  mm; (2) polymicrobial bacteremia (ie, 
bloodstream infection with >1 organism); (3) cefepime discon-
tinued <72 hours after the initial dose; (4) combination anti-
microbial therapy; (5) death <48 hours after the initial cefepime 
dose; or (6) missing or duplicate data.
Microbiology
Before November 2013, bacterial identification was performed 
using phenotypic methods, including VITEK 2, API, and other 
biochemical methods. After November 2013, bacteria identi-
fication was performed using matrix-assisted laser desorption 
ionization–time of flight mass spectrometry (Bruker BioTyper). 
The CLSI-defined Kirby Bauer disk diffusion method was used 
for antimicrobial susceptibility testing at our microbiology lab-
oratory. For the purpose of this study, an extended-spectrum 
beta-lactamases (ESBL)–producing strain was defined based 
on a typical phenotypic susceptibility profile (ie, susceptible to 
cefotetan, resistant to cefazolin, and intermediate or resistant 
to ceftazidime and/or ceftriaxone).We also identified chromo-
somal AmpC β-lactamase-producing Enterobacteriaceae [7].
Clinical Data
We queried the hospital’s Microbiology Laboratory data-
base to identify all Enterobacteriaceae blood isolates during 
the study period. Demographic, microbiologic, treatment, 
and outcome data were extracted from the medical infor-
matics database. Sources of bacteremia were determined 
using International Classification of Diseases 9th Revision, 
Clinical Modification (ICD-9 CM), diagnosis codes. The 
Elixhauser comorbidity index was used to define the severity 
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of underlying health conditions [8] and was dichotomized 
into <3 and ≥3.
The 2014 CLSI cefepime-SDD interpretative category was 
created based on a cefepime dosing regimen of 2 g Q8 hours 
[1]. For this, we categorized cefepime regimens into standard 
dosing of <6 g/d (eg, 1 g Q8 hours or 2 g Q12 hours) and high 
dosing of 6 g/d (ie, 2 g Q8 hours). Cefepime was administered 
through standard infusion over 30–60 minutes at our institu-
tion. Data on serum creatinine, creatinine clearance estimated 
by Cockcroft-Gault formula, and renal replacement therapy 
were collected to account for renal dosage adjustment [9]. 
Bacteremia was classified into community- or nosocomial-
acquired, defined as the first positive blood culture in <48 hours 
or ≥48 hours after hospitalization, respectively.
Outcome
The primary exposure of interest was cefepime susceptibility 
re-categorization of previously identified cefepime-susceptible 
Enterobacteriaceae isolates using the revised CLSI breakpoint, 
dichotomized into cefepime-susceptible and cefepime-SDD. 
The primary outcomes included 30-day all-cause mortality and 
microbiological failure. Microbiological failure was defined as 
subsequent bacteremia with the same organism after 72 hours 
of cefepime treatment and within 30  days of the initial posi-
tive blood culture. Dates of death were extracted from the hos-
pital medical informatics database and from the Social Security 
Death Index.
Statistical Analysis
Data were analyzed using SAS Software (version 9.3; SAS 
Institute Inc., Cary, NC). Demographic characteristics and 
blood culture data were compared based on cefepime sus-
ceptibility status. Categorical variables were assessed using 
the χ 2 test, Fisher exact test, or univariable logistic regression, 
where appropriate. Comparisons of continuous variables were 
done using the Kruskal-Wallis test. To determine the inde-
pendent predictors associated with mortality and microbio-
logical failure, we performed multivariable logistic regression 
analyses. All variables with P <.20 in univariable analyses were 
considered for entry in the model using backwards stepwise re-
gression, with retention in the final model if P <.05. Given that 
cefepime susceptibility was the main independent variable of 
interest, it was forced into both regression models. This study 
was approved by the Human Research Protection Office at 
Washington University in St. Louis.
RESULTS
During the study period, 2776 patients with cefepime-
susceptible Enterobacteriaceae bacteremia were identified; 
664 of these patients met the inclusion criteria. When the new 
breakpoint was applied, 26 (3.9%) isolates were re-categorized 
into cefepime-SDD, and 638 (96.1%) isolates remained 
cefepime-susceptible. Escherichia coli (32.5%) was the most 
commonly isolated Enterobacteriaceae, followed by Klebsiella 
pneumoniae (28.3%), and Enterobacter cloacae complex 
(13.3%). The common sources of bacteremia were genitouri-
nary (33.4%), pulmonary (17.8%), and gastrointestinal infec-
tions (15.5%) (Supplementary Table 1).
Overall, the cefepime-susceptible and cefepime-SDD groups 
were similar with respect to baseline characteristics, source of 
bacteremia, sepsis, renal functions, mode of infection acqui-
sition, and length of stay (Supplementary Table 1). Patients in 
the cefepime-SDD arm were more likely to be of nonwhite race, 
have an Elixhauser comorbidity score of ≥3 (84.6% vs 64.9%; 
P  =  .038), and have isolation of an ESBL-producing isolate 
(34.6% vs 3.4%; P < .001), AmpC β-lactamase-producing isolate 
(50.0% vs 27.7%; P =  .014), and Enterobacter cloacae complex 
(42.4% vs 12.1%; P < .001).
The mortality rate was 11.5% (n  =  3/26) and 10.2% 
(n  =  65/638) in the cefepime-SDD and cefepime-susceptible 
groups, respectively. An Elixhauser comorbidity index of ≥3 
(adjusted odd ratio [aOR], 2.36; 95% confidence interval [CI], 
1.19–4.69) and sepsis (aOR, 2.44; 95% CI, 1.40–4.24) were inde-
pendently associated with 30-day all-cause mortality (Table 1).
Two (7.7%) of 26 patients in the cefepime-SDD group had 
microbiological failure, compared with 19 (3.0%) of 638 in the 
cefepime-susceptible arm. There were no significant independent 
predictors associated with microbiological failure (Table 1).
DISCUSSION
We found that the revised CLSI reporting of Enterobacteriaceae 
changed 3.9% of the previously identified cefepime-susceptible 
isolates to cefepime-SDD. This rate was similar to the previ-
ously published range of 1%–3% [10–12]. Our analyses suggest 
no difference in 30-day all-cause mortality and microbiolog-
ical failure between cefepime-SDD and cefepime-susceptible 
Enterobacteriaceae bacteremia after incorporating 2014 CLSI 
breakpoint on previously collected cefepime-susceptible 
Enterobacteriaceae isolates.
Recent observational studies have suggested that the revised 
CLSI breakpoint for cefepime are associated with increased mor-
tality and microbiological failure in Gram-negative infections 
with higher MICs or cefepime-SDD isolates [2–6]. However, 
these studies were confounded by non-Enterobacteriaceae in-
fections (eg, Pseudomonas aeruginosa and Acinetobacter spe-
cies), polymicrobial infections, and combination antimicrobial 
therapy for treatment of Gram-negative infection [2, 4, 6]. To 
overcome the limitations of previous studies, we used more rig-
orous inclusion criteria. After taking into account confounders, 
our findings suggest that the new 2014 CLSI breakpoint was not 
associated with worse clinical outcomes.
CLSI guidelines assert that, with lower cephalosporin 
 breakpoints, ESBL-producing organisms that would have been 
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be considered resistant [13]. Therefore, routine ESBL detec-
tion in Enterobacteriaceae is no longer recommended for clin-
ical purposes [1]. In our cohort, 4.7% of the cefepime-SDD 
and cefepime-susceptible Enterobacteriaceae isolates pheno-
typically exhibited ESBL production. Emerging clinical data 
have reported higher mortality and inferiority of cefepime to 
carbapenems in treating ESBL-producing Enterobacteriaceae 
infection [3, 5, 14]. ESBL production was not predictive of mor-
tality and microbiological failure in our multivariable analyses. 
However, ESBL screening and cefepime treatment for invasive 
ESBL-producing Enterobacteriaceae infection remain contro-
versial [13, 14].
Pharmacokinetic–pharmacodynamic modeling concluded 
that a 65% fT > MIC for Enterobacteriaceae isolates with MICs of 
4–8 µg/mL was reached at 70%–90% probability with cefepime 
2  g Q8 hours [15]. This prompted a CLSI recommendation 
of high-dose cefepime for cefepime-SDD Enterobacteriaceae 
[1]. We found that only 42.3% of the cefepime-SDD arm re-
ceived high-dose cefepime. There were no differences in mor-
tality or microbiological failure between high- vs standard-dose 
cefepime in patients with cefepime-SDD Enterobacteriaceae 
bacteremia. Because this is a retrospective study, the 2014 CLSI 
recommendation of using high-dose cefepime would not have 
been applied to these previously collected Enterobacteriaceae 
isolates for 2005–2013. Thus, we were unable to fully evaluate 
whether high-dose cefepime would have led to a more favorable 
outcome for patients with cefepime-SDD Enterobacteriaceae 
bacteremia. Future studies are needed to answer this clinical 
question.
This study is limited by a retrospective cohort in a single 
institution, and hence our findings may not be generalizable 
to other populations. Despite a large cohort, only 26 cases of 
cefepime-SDD Enterobacteriaceae were identified due to its 
infrequency. This limited our statistical power. Although our 
database was built to maximize comprehensiveness, ICD-9 
CM codes may not accurately reflect the true infectious di-
agnosis and may result in misclassification bias. Additionally, 
we were unable to identify source control that may have con-
tributed to variations in clinical outcomes. Lastly, the pres-
ence of ESBL production was determined phenotypically in 
our study. However, this would also be particularly relevant 
in real-world practice, as accessibility to molecular assay may 
be limited.
In conclusion, we found no differences in mortality or mi-
crobiological failure among cases of Enterobacteriaceae bac-
teremia treated with cefepime, regardless of isolates being 
either cefepime-susceptible or cefepime-SDD by current CLSI 
standards.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
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the posted materials are not copyedited and are the sole responsibility of 
the authors, so questions or comments should be addressed to the corre-
sponding author.
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